Skip to contentP
Pulse Biosciences, Inc.
P
PLSEPulse Biosciences, Inc. Q3 2023 · 10-Q
Revenue$0.00$0.00— vs Q3 2022 Net Income-$10.57M-$10.57MN/M vs Q3 2022 EPS, diluted—
Operating Income-$11,252,000N/M Operating Cash Flowderived-$10,487,000N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Pulse Biosciences, Inc. · CIK 1625101 · Engraved from SEC EDGAR
Free Cash Flowderived-$10,510,000N/M ended Sep 30, 2023 · filed Nov 13, 2023 · 44 d after period end